Bortezomib restrains M2 polarization and reduces CXCL16-associated CXCR6⁺CD4 T cell chemotaxis in bleomycin-induced pulmonary fibrosis.

ABSTRACT:

Background

The development of pulmonary fibrosis involves a cascade of events, in which inflammation mediated by immune cells plays a pivotal role. Chemotherapeutic drugs have been shown to have dual effects on fibrosis, with bleomycin exacerbating pulmonary fibrosis and bortezomib alleviating tissue fibrotic processes. Understanding the intricate interplay between chemotherapeutic drugs, immune responses, and pulmonary fibrosis is likely to serve as the foundation for crafting tailored therapeutic strategies.

Methods

A model of bleomycin-induced pulmonary fibrosis was established, followed by treatment with bortezomib. Tissue samples were collected for analysis of immune cell subsets and functional assessment by flow cytometry and in vitro cell experiments. Additionally, mu

SUBMITTER: Zhou T 

PROVIDER: S-EPMC11127379 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature